Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/13/2005CA2564018A1 8-phenoxy-.gamma. carboline derivatives
10/13/2005CA2563117A1 Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor
10/13/2005CA2563038A1 Neurologically-active compounds
10/13/2005CA2562944A1 Adiponectin enhancer
10/13/2005CA2562700A1 Novel pharmaceutical compositions
10/13/2005CA2562126A1 Pyrazine derivatives and pharmaceutical use thereof
10/13/2005CA2562123A1 Thiazole-amine compounds for the treatment of neurodegenerative disorders
10/13/2005CA2562114A1 Sulfonamide compounds for the treatment of neurodegenerative disorders
10/13/2005CA2562106A1 Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
10/13/2005CA2562039A1 Heterocyclic cgrp antagonists for the treatment of migraine
10/13/2005CA2561977A1 Substituted thiophene derivatives as anti-cancer agents
10/13/2005CA2561896A1 Antiviral agents
10/13/2005CA2561883A1 Treatment of impaired respiratory function with gaboxadol
10/13/2005CA2561729A1 Skin beautifier
10/13/2005CA2561596A1 Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
10/13/2005CA2561577A1 Therapeutic use of a growth factor, nsg33
10/13/2005CA2561560A1 Hydrazide-containing cftr inhibitor compounds and uses thereof
10/13/2005CA2561516A1 Combinations of signal transduction inhibitors
10/13/2005CA2561513A1 Effective treatment of tumors and cancer with triciribine and related compounds
10/13/2005CA2561441A1 Pyrazole-amine compounds for the treatment of neurodegenerative disorders
10/13/2005CA2561417A1 Novel thiazolopyrazoles and methods of their use
10/13/2005CA2561401A1 Process for producing flavone c glycoside derivatives
10/13/2005CA2561400A1 Chemical process and new crystalline form
10/13/2005CA2561394A1 Production and use of the methotrexate-albumin conjugate as an immunosuppressive agent in gvhd
10/13/2005CA2561383A1 Prophylactic and/or therapeutic agents for chronic musculoskeletal pain
10/13/2005CA2561380A1 A composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity
10/13/2005CA2561305A1 Tetrahydro-indazole cannabinoid modulators
10/13/2005CA2561157A1 Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
10/13/2005CA2561116A1 Therapeutic agents, methods, and treatments
10/13/2005CA2560878A1 Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils
10/13/2005CA2560866A1 Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (ryr2) and uses thereof
10/13/2005CA2560826A1 Antioxidant-promoting herbal extract compositions for alleviating oxidative stress in a mammal
10/13/2005CA2560824A1 Use of loteprednol etabonate for the treatment of dry eye
10/13/2005CA2560822A1 Geldanamycin and derivatives inhibit cancer invasion and identify novel targets
10/13/2005CA2560818A1 Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester
10/13/2005CA2560812A1 Coated tablet formulation and method
10/13/2005CA2560776A1 Vegetable based dioxanone derivatives, synthesis and uses thereof
10/13/2005CA2560773A1 2-amino- and 2-thio-substituted 1,3-diaminopropanes
10/13/2005CA2560691A1 Tricyclic pyrazole kinase inhibitors
10/13/2005CA2560684A1 Substituted 1,4,8-triazaspiro[4.5]decan-2-one compounds
10/13/2005CA2560595A1 Multi-vitamin and mineral nutritional supplements
10/13/2005CA2560256A1 Heteroaryl piperidine glycine transporter inhibitors
10/13/2005CA2560005A1 Phenol derivative, medicinal composition containing the same, and medicinal use thereof
10/13/2005CA2559992A1 Novel water-soluble fullerene, process for producing the same and active oxygen generator containing the fullerene
10/13/2005CA2559948A1 Beta-aminoacid-derivatives as factor xa inhibitors
10/13/2005CA2559945A1 Pyrazole compounds and uses related thereto
10/13/2005CA2559712A1 Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
10/13/2005CA2559141A1 Methods for interfering with fibrosis
10/13/2005CA2559136A1 Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
10/13/2005CA2559005A1 Melanin-concentrating hormone receptor antagonists and methods of use
10/13/2005CA2558923A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
10/13/2005CA2558915A1 Pyrimidine derivatives and methods of treatment related to the use thereof
10/13/2005CA2558615A1 Azabicyclo-octane inhibitors of iap
10/13/2005CA2558607A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
10/13/2005CA2558446A1 Dpp-iv inhibitors
10/13/2005CA2558019A1 Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
10/13/2005CA2557999A1 Methods and compositions for treatment of ion imbalances
10/13/2005CA2557998A1 Combination therapy for weight management
10/13/2005CA2557869A1 Inhibition of mixed lineage kinases and uses therefor
10/13/2005CA2557719A1 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy
10/13/2005CA2557402A1 Pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
10/13/2005CA2557393A1 Oxidized thioether derivatives of styryl-azoles and their use as her tyrosine kinases inhibitors
10/13/2005CA2557372A1 Diaminopyrimidines as p2x3 and p2x2/3 antagonists
10/13/2005CA2557166A1 Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
10/13/2005CA2556227A1 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
10/13/2005CA2554551A1 Compositions useful as inhibitors of protein kinases
10/13/2005CA2552542A1 Controlled release pharmaceutical composition of tolperisone for oral administration
10/13/2005CA2551797A1 Anionic hydrogel matrices with ph dependent modified release as drug carriers
10/13/2005CA2544499A1 Activation of hypoxia-inducible gene expression
10/13/2005CA2539043A1 Compositions capable of facilitating penetration across a biological barrier
10/12/2005EP1584925A1 Novel screening method
10/12/2005EP1584682A1 Regulation of bcl-2 gene expression
10/12/2005EP1584622A2 Compounds for the photodecontamination of pathogens in blood
10/12/2005EP1584619A1 Derivatives of quinoline as inhibitors for MEK
10/12/2005EP1584373A2 Zeolite y alkylation catalysts
10/12/2005EP1584335A2 Active substance combination comprising a carbinol composition and an opioid
10/12/2005EP1584334A2 Solution based methacholine formulations
10/12/2005EP1584333A2 Use of acetylcoenzime A inhibitors for treating Alzheimer's disease
10/12/2005EP1583971A2 Modulation of deubiquitinase family members
10/12/2005EP1583765A2 Compositions for treating and/or preventing diseases characterized by the presence of metal ions
10/12/2005EP1583763A1 Benzoazolypiperazine derivatives having mglur1- and mglur5-antagonistic activity
10/12/2005EP1583762A1 Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
10/12/2005EP1583760A2 Substituted heterocyclic compounds
10/12/2005EP1583747A2 Inhibitors of phosphatases
10/12/2005EP1583744A2 Substituted benzylamine derivatives and methods of use
10/12/2005EP1583742A1 Novel cb 1 receptour inverse agonists
10/12/2005EP1583737A1 Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester
10/12/2005EP1583735A2 Novel aminobenzophenone compounds
10/12/2005EP1583559A1 Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers
10/12/2005EP1583552A2 Antineoplastic ether lipid compounds
10/12/2005EP1583546A2 Modulation of zinc levels to improve tissue properties
10/12/2005EP1583544A2 Method of treatment for central nervous system injury
10/12/2005EP1583543A2 Methods and therapeutic compositions in the treatment of advanced cancer
10/12/2005EP1583542A1 Compositions and methods for combination antiviral therapy
10/12/2005EP1583541A2 Compounds and methods for increasing neurogenesis
10/12/2005EP1583540A1 Method of treating patients exposed to toxic chemical agents
10/12/2005EP1583539A2 Paricalcitol as a chemotherapeutic agent
10/12/2005EP1583538A1 Use of 3-methoxy-pregnenolone in the production of a medicament for treating neurodegenerative diseases
10/12/2005EP1583537A2 Piperidine compounds as antibacterials
10/12/2005EP1583536A2 Method of treatment of prostate cancer and composition for treatment thereof
1 ... 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 4526 4527 ... 7860